Literature DB >> 28893982

Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF.

Ken-Ichi Takayama1, Takashi Suzuki2, Tetsuya Fujimura3, Yuta Yamada3, Satoru Takahashi4, Yukio Homma3, Yutaka Suzuki5, Satoshi Inoue6,7.   

Abstract

Developing therapeutic approaches are necessary for treating hormone-refractory prostate cancer. Activation of androgen receptor (AR) and its variants' expression along with the downstream signals are mostly important for disease progression. However, the mechanism for marked increases of AR signals and its expression is still unclear. Here, we revealed that various spliceosome genes are aberrantly induced by RNA-binding protein PSF, leading to enhancement of the splicing activities for AR expression. Our high-speed sequence analyses identified global PSF-binding transcripts. PSF was shown to stabilize and activate key long noncoding RNAs and AR-regulated gene expressions in prostate cancer cells. Interestingly, mRNAs of spliceosome-related genes are putative primary targets of PSF. Their gene expressions are up-regulated by PSF in hormone-refractory prostate cancer. Moreover, PSF coordinated these spliceosome proteins to form a complex to promote AR splicing and expression. Thus, targeting PSF and its related pathways implicates the therapeutic possibility for hormone-refractory prostate cancer.

Entities:  

Keywords:  NONO; PSF; RNA-binding protein; androgen receptor; prostate cancer

Mesh:

Substances:

Year:  2017        PMID: 28893982      PMCID: PMC5625911          DOI: 10.1073/pnas.1706076114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Molecular architecture of the multiprotein splicing factor SF3b.

Authors:  Monika M Golas; Bjoern Sander; Cindy L Will; Reinhard Lührmann; Holger Stark
Journal:  Science       Date:  2003-05-09       Impact factor: 47.728

2.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Authors:  Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

Review 3.  Androgen receptor (AR) aberrations in castration-resistant prostate cancer.

Authors:  Kati K Waltering; Alfonso Urbanucci; Tapio Visakorpi
Journal:  Mol Cell Endocrinol       Date:  2012-01-08       Impact factor: 4.102

4.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

Authors:  Sooryanarayana Varambally; Jianjun Yu; Bharathi Laxman; Daniel R Rhodes; Rohit Mehra; Scott A Tomlins; Rajal B Shah; Uma Chandran; Federico A Monzon; Michael J Becich; John T Wei; Kenneth J Pienta; Debashis Ghosh; Mark A Rubin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

5.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

6.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

7.  Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer.

Authors:  Ken-Ichi Takayama; Kuniko Horie-Inoue; Shintaro Katayama; Takashi Suzuki; Shuichi Tsutsumi; Kazuhiro Ikeda; Tomohiko Urano; Tetsuya Fujimura; Kiyoshi Takagi; Satoru Takahashi; Yukio Homma; Yasuyoshi Ouchi; Hiroyuki Aburatani; Yoshihide Hayashizaki; Satoshi Inoue
Journal:  EMBO J       Date:  2013-05-03       Impact factor: 11.598

8.  The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis.

Authors:  Charles E Massie; Andy Lynch; Antonio Ramos-Montoya; Joan Boren; Rory Stark; Ladan Fazli; Anne Warren; Helen Scott; Basetti Madhu; Naomi Sharma; Helene Bon; Vinny Zecchini; Donna-Michelle Smith; Gina M Denicola; Nik Mathews; Michelle Osborne; James Hadfield; Stewart Macarthur; Boris Adryan; Scott K Lyons; Kevin M Brindle; John Griffiths; Martin E Gleave; Paul S Rennie; David E Neal; Ian G Mills
Journal:  EMBO J       Date:  2011-05-20       Impact factor: 11.598

9.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

10.  The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.

Authors:  John R Prensner; Matthew K Iyer; Anirban Sahu; Irfan A Asangani; Qi Cao; Lalit Patel; Ismael A Vergara; Elai Davicioni; Nicholas Erho; Mercedeh Ghadessi; Robert B Jenkins; Timothy J Triche; Rohit Malik; Rachel Bedenis; Natalie McGregor; Teng Ma; Wei Chen; Sumin Han; Xiaojun Jing; Xuhong Cao; Xiaoju Wang; Benjamin Chandler; Wei Yan; Javed Siddiqui; Lakshmi P Kunju; Saravana M Dhanasekaran; Kenneth J Pienta; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2013-09-29       Impact factor: 38.330

View more
  30 in total

1.  LncRNA AC245100.4 binds HSP90 to promote the proliferation of prostate cancer.

Authors:  Rongjun Cui; Chi Liu; Ping Lin; Hui Xie; Wei Wang; Jiabin Zhao; Shan Jiang; Jie Shi; Xiaoguang Yu
Journal:  Epigenomics       Date:  2020-08-19       Impact factor: 4.778

2.  COBLL1 modulates cell morphology and facilitates androgen receptor genomic binding in advanced prostate cancer.

Authors:  Ken-Ichi Takayama; Takashi Suzuki; Tetsuya Fujimura; Satoru Takahashi; Satoshi Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-23       Impact factor: 11.205

3.  Prostate cancer: Alternatively spliced mRNA transcripts in tumor progression and their uses as therapeutic targets.

Authors:  Ali Calderon-Aparicio; Bi-Dar Wang
Journal:  Int J Biochem Cell Biol       Date:  2021-10-13       Impact factor: 5.085

4.  SFPQ promotes RAS-mutant cancer cell growth by modulating 5'-UTR mediated translational control of CK1α.

Authors:  Venetia Jing Tong Kok; Jia Ying Tang; Gracie Wee Ling Eng; Shin Yi Tan; Joseph Tin Foong Chin; Chun Hian Quek; Wei Xuan Lai; Teck Kwang Lim; Qingsong Lin; John Jia En Chua; Jit Kong Cheong
Journal:  NAR Cancer       Date:  2022-09-27

Review 5.  Emerging Proteins in CRPC: Functional Roles and Clinical Implications.

Authors:  Piaoping Kong; Lingyu Zhang; Zhengliang Zhang; Kangle Feng; Yiwen Sang; Xiuzhi Duan; Chunhua Liu; Tao Sun; Zhihua Tao; Weiwei Liu
Journal:  Front Oncol       Date:  2022-06-10       Impact factor: 5.738

6.  PSPC1 is a potential prognostic marker for hormone-dependent breast cancer patients and modulates RNA processing of ESR1 and SCFD2.

Authors:  Toshihiko Takeiwa; Kazuhiro Ikeda; Takashi Suzuki; Wataru Sato; Kaori Iino; Yuichi Mitobe; Hidetaka Kawabata; Kuniko Horie; Satoshi Inoue
Journal:  Sci Rep       Date:  2022-06-09       Impact factor: 4.996

7.  The origin of exosomal miR-1246 in human cancer cells.

Authors:  Yi-Fan Xu; Bethany N Hannafon; Ujjwol Khatri; Amy Gin; Wei-Qun Ding
Journal:  RNA Biol       Date:  2019-03-23       Impact factor: 4.652

Review 8.  AR Splicing Variants and Resistance to AR Targeting Agents.

Authors:  Mayuko Kanayama; Changxue Lu; Jun Luo; Emmanuel S Antonarakis
Journal:  Cancers (Basel)       Date:  2021-05-23       Impact factor: 6.639

9.  Long non-coding RNA SNHG1 suppresses cell migration and invasion and upregulates SOCS2 in human gastric carcinoma.

Authors:  Shanshan Wang; Haibo Han; Junling Meng; Wei Yang; Yunwei Lv; Xianzi Wen
Journal:  Biochem Biophys Rep       Date:  2021-06-17

10.  Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer.

Authors:  Ken-Ichi Takayama; Takeo Kosaka; Takashi Suzuki; Hiroshi Hongo; Mototsugu Oya; Tetsuya Fujimura; Yutaka Suzuki; Satoshi Inoue
Journal:  Nat Commun       Date:  2021-06-18       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.